JP2013538566A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013538566A5 JP2013538566A5 JP2013523643A JP2013523643A JP2013538566A5 JP 2013538566 A5 JP2013538566 A5 JP 2013538566A5 JP 2013523643 A JP2013523643 A JP 2013523643A JP 2013523643 A JP2013523643 A JP 2013523643A JP 2013538566 A5 JP2013538566 A5 JP 2013538566A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- dom7h
- acid sequence
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 238000006467 substitution reaction Methods 0.000 claims 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 6
- 102000009027 Albumins Human genes 0.000 claims 5
- 108010088751 Albumins Proteins 0.000 claims 5
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 238000010494 dissociation reaction Methods 0.000 claims 4
- 230000005593 dissociations Effects 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- HAYVTMHUNMMXCV-IMJSIDKUSA-N Cys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CS HAYVTMHUNMMXCV-IMJSIDKUSA-N 0.000 claims 1
- OPINTGHFESTVAX-BQBZGAKWSA-N Gln-Arg Chemical group NC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N OPINTGHFESTVAX-BQBZGAKWSA-N 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- QNBYCZTZNOVDMI-HGNGGELXSA-N Ile-His Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 QNBYCZTZNOVDMI-HGNGGELXSA-N 0.000 claims 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- BXNGIHFNNNSEOS-UWVGGRQHSA-N Phe-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 BXNGIHFNNNSEOS-UWVGGRQHSA-N 0.000 claims 1
- JMCOUWKXLXDERB-WMZOPIPTSA-N Phe-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 JMCOUWKXLXDERB-WMZOPIPTSA-N 0.000 claims 1
- NFDYGNFETJVMSE-BQBZGAKWSA-N Ser-Leu Chemical group CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CO NFDYGNFETJVMSE-BQBZGAKWSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 108010083476 phenylalanyltryptophan Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37339710P | 2010-08-13 | 2010-08-13 | |
| US61/373,397 | 2010-08-13 | ||
| PCT/EP2011/063999 WO2012020143A1 (en) | 2010-08-13 | 2011-08-12 | Improved anti-serum albumin binding variants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013538566A JP2013538566A (ja) | 2013-10-17 |
| JP2013538566A5 true JP2013538566A5 (enExample) | 2014-09-18 |
Family
ID=44582954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013523643A Pending JP2013538566A (ja) | 2010-08-13 | 2011-08-12 | 改良された抗血清アルブミン結合変異体 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US9012609B2 (enExample) |
| EP (1) | EP2603522A1 (enExample) |
| JP (1) | JP2013538566A (enExample) |
| WO (1) | WO2012020143A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010092135A2 (en) | 2009-02-11 | 2010-08-19 | Novozymes Biopharma Uk Ltd. | Albumin variants and conjugates |
| RU2607374C2 (ru) | 2009-10-30 | 2017-01-10 | Новозаймс Байофарма Дк А/С | Варианты альбумина |
| KR20130070576A (ko) | 2010-04-09 | 2013-06-27 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 유도체 및 변이체 |
| WO2012020143A1 (en) * | 2010-08-13 | 2012-02-16 | Glaxo Group Limited | Improved anti-serum albumin binding variants |
| EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| PL2825556T3 (pl) | 2012-03-16 | 2018-10-31 | Albumedix A/S | Warianty albuminy |
| AU2013343503B2 (en) | 2012-11-08 | 2017-12-14 | Albumedix Ltd. | Albumin variants |
| US20160222087A1 (en) * | 2013-09-13 | 2016-08-04 | Novozymes Biopharma Dk A/S | Albumin variants |
| EP3337816B1 (en) | 2015-08-20 | 2024-02-14 | Albumedix Ltd | Albumin variants and conjugates |
| SI3374392T1 (sl) * | 2015-11-13 | 2022-04-29 | Ablynx Nv | Izboljšane variabilne domene imunoglobulina, ki vežejo serumski albumin |
| KR20230074598A (ko) | 2016-05-18 | 2023-05-30 | 모더나티엑스, 인크. | 릴랙신을 인코딩하는 폴리뉴클레오타이드 |
| KR20230061582A (ko) * | 2016-12-07 | 2023-05-08 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인 |
| LT3571225T (lt) | 2017-01-17 | 2024-11-11 | Ablynx Nv | Patobulintos serumo albumino rišamosios medžiagos |
| RS66173B1 (sr) | 2017-01-17 | 2024-12-31 | Ablynx NV | Poboljšana veziva serumskog albumina |
| JP7200138B2 (ja) | 2017-02-16 | 2023-01-06 | ソネット バイオセラピューティクス,インコーポレイテッド | アルブミン結合ドメイン融合タンパク質 |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| US12134635B1 (en) | 2023-12-29 | 2024-11-05 | Sonnet BioTherapeutics, Inc. | Interleukin 18 (IL-18) variants and fusion proteins comprising same |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291189B1 (en) | 1994-05-10 | 2001-09-18 | Carta Proteomics, Inc. | Methods for the high-resolution identification of solvent-accessible amide hydrogens in polypeptides or proteins and for characterization of the fine structure of protein binding sites |
| US5658739A (en) | 1994-05-10 | 1997-08-19 | The Regents Of The University Of California | Method for characterization of the fine structure of protein binding sites |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| WO2004003019A2 (en) | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| WO2004035751A2 (en) | 2002-10-18 | 2004-04-29 | The Regents Of The University Of California | Methods for crystallographic structure determination employing hydrogen exchange analysis |
| EP2172553A1 (en) | 2004-03-24 | 2010-04-07 | Domantis Limited | Gas1 universal leader |
| CA2569240A1 (en) | 2004-06-01 | 2005-12-15 | Domantis Limited | Drug fusion comprising a polypeptide drug and an immunoglobulin heavy chain variable domain specific for serum albumin |
| GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| WO2006059106A2 (en) | 2004-12-02 | 2006-06-08 | Domantis Limited | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
| EP1976991A1 (en) | 2006-01-24 | 2008-10-08 | Domantis Limited | Fusion proteins that contain natural junctions |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| CA2688433A1 (en) * | 2007-06-06 | 2008-12-11 | Domantis Limited | Methods for selecting protease resistant polypeptides |
| WO2009068649A2 (en) | 2007-11-30 | 2009-06-04 | Glaxo Group Limited | Antigen-binding constructs |
| KR101740066B1 (ko) | 2008-12-05 | 2017-05-25 | 글락소 그룹 리미티드 | 프로테아제 저항성 폴리펩티드를 선택하는 방법 |
| WO2010081787A1 (en) | 2009-01-14 | 2010-07-22 | Domantis Limited | IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS |
| KR101819754B1 (ko) * | 2009-02-19 | 2018-01-18 | 글락소 그룹 리미티드 | 개선된 항-혈청 알부민 결합 변이체 |
| ES2654929T3 (es) | 2009-02-19 | 2018-02-15 | Glaxo Group Limited | Variantes de unión de anti-albúmina de suero mejoradas |
| CN102574914A (zh) | 2009-07-16 | 2012-07-11 | 葛兰素集团有限公司 | 改进的抗血清清蛋白结合性单可变区 |
| CA2774552A1 (en) * | 2009-09-30 | 2011-04-07 | Glaxo Group Limited | Drug fusions and conjugates with extended half life |
| WO2012020143A1 (en) * | 2010-08-13 | 2012-02-16 | Glaxo Group Limited | Improved anti-serum albumin binding variants |
-
2011
- 2011-08-12 WO PCT/EP2011/063999 patent/WO2012020143A1/en not_active Ceased
- 2011-08-12 EP EP11743554.5A patent/EP2603522A1/en not_active Withdrawn
- 2011-08-12 US US13/816,515 patent/US9012609B2/en not_active Expired - Fee Related
- 2011-08-12 JP JP2013523643A patent/JP2013538566A/ja active Pending
-
2015
- 2015-02-27 US US14/633,463 patent/US20160052998A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013538566A5 (enExample) | ||
| RU2577228C2 (ru) | Анти-il-17-антитела, способ их получения и способ применения | |
| JP2013529080A5 (enExample) | ||
| JP2016539096A5 (enExample) | ||
| JP2017520575A5 (enExample) | ||
| HRP20161043T1 (hr) | Ljudska antitijela visokog afiniteta u odnosu na ljudski angiopoietin-2 | |
| RS66117B1 (sr) | Poboljšana veziva serumskog albumina | |
| RS66173B1 (sr) | Poboljšana veziva serumskog albumina | |
| ME00519B (me) | Antitijela visokog afiniteta prema humanom il-6 receptoru | |
| RU2019123112A (ru) | Анти-il-5 антитела | |
| IL266907B1 (en) | Improved serum albumin binding immunoglobulin single variable domains | |
| CN104245736B (zh) | 抗人死亡受体5胞外区的人源化单克隆抗体 | |
| RU2017144098A (ru) | Гетеродимеризованный полипептид | |
| JP2013519721A5 (enExample) | ||
| JP2017506075A5 (enExample) | ||
| IL276286B2 (en) | FC variants with improved binding to FCRN and extended half-life | |
| JP2009539349A5 (enExample) | ||
| JP2012515556A5 (enExample) | ||
| JP2015530983A5 (enExample) | ||
| JP2021530207A (ja) | 二重特異性抗体及びその使用 | |
| JP2018509887A5 (enExample) | ||
| JP2014534237A5 (enExample) | ||
| JP2014530001A5 (enExample) | ||
| US20150175708A1 (en) | Multifunctional Antibodies Binding to EGFR and MET | |
| JP2016512214A5 (enExample) |